Cosmo Pharmaceuticals N.V. (“Cosmo”) reports strong preliminary unaudited 2025 revenue and year end cash, reflecting continued revenue growth and a robust cash position. Cosmo will publish its 2025 audited consolidated financial statements as well as the Annual and ESG Reports 2025 on March 9, 2026.
2025 marks a key execution year in Cosmo’s Vision 2030, strengthening the Company’s foundations for scalable, innovation-driven growth across AI-enabled MedTech and pharma.